profit from every $100 of sales.
$0$100
Quest Diagnostics
$259.65+0.37% today
+39.0% in 1 year
1-year low $173.491-year high $259.67
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $28.79 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Quest Diagnostics sold, what it kept, and what it did with the cash.
Sales went from $9.88 billion in 2022 to $11.0 billion in 2025, with $992 million of profit last year.
SalesProfit
Quest Diagnostics handed back 59% of the cash it generated last year.
Buybacks $450M$353M
Free cash flow 2025$1.4B
Bought back its own shares$450M
Paid as dividends$353M
Cash vs. debt$420M vs. $6.6B
Quest Diagnostics vs. similar companies
Quest Diagnostics grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Quest Diagnostics | 28.8× · Fair price | ||
 Illumina | 37.3× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Guardant Health | No profit yet | ||
 Exact Sciences | No profit yet |
Compare Quest Diagnostics with Labcorp Holdings · Natera
AI analysis
An AI analyst reads Quest Diagnostics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 9,437 | 10,788 | 9,883 | 9,252 | 9,872 | 11,035 | |
| 3,633 | 4,209 | 3,433 | 3,053 | 3,244 | 3,665 | |
| 1,971 | 2,381 | 1,428 | 1,262 | 1,346 | 1,556 | |
| 2,411 | 3,159 | 1,820 | 1,732 | 1,894 | 2,165 | |
| 1,431 | 1,995 | 946 | 854 | 871 | 992 | |
| 10.47 | 15.55 | 7.97 | 7.49 | 7.69 | 8.75 | |
| 38.5% | 39.0% | 34.7% | 33.0% | 32.9% | 33.2% | |
| 20.9% | 22.1% | 14.4% | 13.6% | 13.6% | 14.1% | |
| 15.2% | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 14,026 | 13,611 | 12,837 | 14,022 | 16,153 | 16,225 |
| Cash | 1,158 | 872 | 315 | 686 | 549 | 420 |
| Total debt | 4,682 | 4,691 | 4,714 | 5,498 | 7,087 | 6,585 |
| Total liabilities | – | – | 6,830 | 7,604 | 9,257 | 8,939 |
| 6,759 | 6,444 | 5,893 | 6,307 | 6,778 | 7,170 | |
| 136 | 128 | 118 | 113 | 113 | 113 | |
| 14.2% | 19.5% | 10.3% | 8.7% | 8.0% | 9.2% | |
| 21.2% | 31.0% | 16.1% | 13.5% | 12.9% | 13.8% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,005 | 2,233 | 1,718 | 1,272 | 1,334 | 1,886 | |
| 418 | 403 | 404 | 408 | 425 | 527 | |
| 1,587 | 1,830 | 1,314 | 864 | 909 | 1,359 | |
| Dividends paid | 297 | 309 | 305 | 314 | 331 | 353 |
| 325 | 2,199 | 1,408 | 275 | 151 | 450 | |
| 97 | 79 | 77 | 77 | 88 | 88 |
Valuation
- 28.8×
- 24.2×
- –
- 2.8×
- 2.6×
- 21.0×
- 16.0×
- 4.8%
- 3.5%
- 1.7%
Profitability
- 33.2%
- 14.1%
- 9.0%
- 17.6%
- 8.1%
- 9.5%
- 14.1%
- 6.1%
- 11.1%
- –
Growth
- +3.2%
- −3.5%
- +49.5%
- +7.3%
- −2.9%
Financial health
- 3.3×
- 0.95
- 41.9%
- 6.1×
- 1.18
- 1.08
- 0.68
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 39%of 952
Top 37%of 883
Bottom 47%of 576
Bottom 22%of 870
Top 23%of 985
What analysts expect
- Average price target
- $220.57
- Range
- $210.00 – $235.00
- 9 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 21, 2026 | 2.50 | 2.37 | +5.5% |
| Feb 10, 2026 | 2.42 | 2.36 | +2.5% |
| Oct 21, 2025 | 2.60 | 2.50 | +4.0% |
| Jul 22, 2025 | 2.62 | 2.57 | +1.9% |
| Apr 22, 2025 | 2.21 | 2.15 | +2.8% |
| Jan 30, 2025 | 2.23 | 2.19 | +1.8% |
| Oct 22, 2024 | 2.30 | 2.26 | +1.8% |
| Jul 23, 2024 | 2.35 | 2.34 | +0.4% |
1.7%of the share price, paid each year
On $1,000 invested$17a year at today's yield, before tax
+7.3%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$1.47 in 2015 → $3.15 in 2025
How safe it looks
35.6% of its profit
Room to growStretchedMore than it earns: 26.0%
News
Quest Diagnostics Incorporated Q3 2026 Earnings Call SummaryYahoo Finance · Oct 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
41No pass
Philip Fisher
38No pass
Peter Lynch
22No pass
Joel Greenblatt
21No pass
Charlie Munger
35No pass
Terry Smith
35No pass
Questions about Quest Diagnostics
Is Quest Diagnostics a good stock to buy?
A business with weak numbers at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Quest Diagnostics AI analysis
What does Quest Diagnostics do?
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. It is in Medical - Diagnostics & Research, based in Secaucus, NJ, United States, with 57,000 employees.
Does Quest Diagnostics pay a dividend?
Yes. At today's price the dividend is 1.7% a year, about 36% of its yearly profit. In 2025 it paid out $353 million in dividends.
Is Quest Diagnostics stock halal?
Yes. Quest Diagnostics passes our halal screen: its business is permitted and its debt is 23% of its market value, under the 30% limit. How we check
How has Quest Diagnostics stock done over the past year?
Up 39.0% over the past twelve months, to $259.65. It traded between $173.49 and $259.67, close to its high.
Who are Quest Diagnostics's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Guardant Health and Exact Sciences. The peers table on this page compares their profit, growth and price with Quest Diagnostics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.